Warts Therapeutics Market - 2021
The Warts Therapeutics Market was valued at USD 1914.25 Million in 2021 and is anticipated to reach by , at a CAGR of 0.049 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Warts Therapeutics Market.
This report delivers a comprehensive overview of the Warts Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Warts Therapeutics Market. The Warts Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
Warts Therapeutics Market Scope:
By Wart Type
This report delivers a comprehensive overview of the Warts Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Warts Therapeutics Market. The Warts Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Warts Therapeutics Market.
This report delivers a comprehensive overview of the Warts Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Warts Therapeutics Market. The Warts Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
Warts Therapeutics Market Scope:
By Wart Type
- Common wart (verruca vulgaris)
- Flat wart, or plane wart (verruca plana)
- Plantar wart, or verruca (verruca plantaris)
- Genital wart (condyloma acuminatum)
- Others( Periungual wart, Filiform wart, Mosaic warts)
- Physical Destruction
- Medication
- Hospitals
- Clinics
- Others
- Merck & Co., Inc.
- Dr. Scholl’s
- Mylan N.V.
- Novan Inc.
- Pfizer, Inc.
- GlaxoSmithKline plc,
- Teva Pharmaceutical Industries Ltd
- Verrica Pharmaceuticals
- Phio Pharmaceuticals Corp.
- AIM ImmunoTech, Inc.
This report delivers a comprehensive overview of the Warts Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Warts Therapeutics Market. The Warts Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Wart Type
3.2. Market Snippet by Treatment Type
3.3. Market Snippet by End-User
3.4. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence of Wart
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulatory approvals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Pipeline Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY WART TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type Segment
7.1.2. Market Attractiveness Index, By Wart Type Segment
7.2. Common wart (verruca vulgaris)*
7.2.1. Introduction
7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3. Flat wart, or plane wart (verruca plana)
7.4. Plantar wart, or verruca (verruca plantaris)
7.5. Genital wart (condyloma acuminatum)
7.6. Others( Periungual wart, Filiform wart, Mosaic warts)
8. BY TREATMENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Physical Destruction*
8.2.1.1. Introduction
8.2.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.2.2. Cryotherapy (Freezing)
8.2.3. Surgical Removal
8.2.4. Laser Treatment
8.2.5. Others
8.3. Medication
8.3.1. Chemical Destruction
8.3.1.1. Bleomycin intralesional
8.3.1.2. Cantharidin (VP-102)
8.3.1.3. Salicylic Acid
8.3.1.4. Others
8.3.2. Immunomodulatory agent
8.3.2.1. Imiquimod 5% - topical
8.3.2.2. Interferon - intralesional
8.3.2.3. Dinitrochlorobenzene - topical
8.3.2.4. Diphencyprone topical
8.3.2.5. Retinoids - topical or oral
8.3.2.6. Others
8.3.3. Vaccines
8.3.3.1. Human papillomavirus vaccine, nonavalent (Gardasil 9)
8.3.3.2. Cervarix
8.3.4. Keratolytics
8.3.4.1. Podophyllum resin (Podocon-25, Podo-Ben-25, Podofin)
8.3.4.2. Podofilox (Condylox)
8.3.4.3. Trichloroacetic acid topical (Tri-Chlor)
8.3.4.4. 5-Fluorouracil (Efudex, Fluoroplex)
8.3.4.5. Others
8.3.5. Kunecatechins (Veregen)
8.3.6. Other
9. BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User Segment
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Others
10. BY REGION
10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.3. Market Attractiveness Index, By Region
10.4. North America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. U.S.
10.4.6.2. Canada
10.4.6.3. Mexico
10.5. Europe
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. Germany
10.5.6.2. U.K.
10.5.6.3. France
10.5.6.4. Italy
10.5.6.5. Spain
10.5.6.6. Rest of Europe
10.6. South America
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.6.7.1. Brazil
10.6.7.2. Argentina
10.6.7.3. Rest of South America
10.7. Asia Pacific
10.7.1. Introduction
10.7.2. Key Region-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.7.6.1. China
10.7.6.2. India
10.7.6.3. Japan
10.7.6.4. Australia
10.7.6.5. Rest of Asia Pacific
10.8. Middle East and Africa
10.8.1. Introduction
10.8.2. Key Region-Specific Dynamics
10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. COMPANY PROFILES
12.1. Merck & Co., Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Dr. Scholl’s
12.3. Mylan N.V.
12.4. Novan Inc.
12.5. Pfizer, Inc.
12.6. GlaxoSmithKline plc,
12.7. Teva Pharmaceutical Industries Ltd
12.8. Verrica Pharmaceuticals
12.9. Phio Pharmaceuticals Corp.
12.10. AIM ImmunoTech, Inc. (List Not Exhaustive)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Wart Type
3.2. Market Snippet by Treatment Type
3.3. Market Snippet by End-User
3.4. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence of Wart
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulatory approvals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Pipeline Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY WART TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type Segment
7.1.2. Market Attractiveness Index, By Wart Type Segment
7.2. Common wart (verruca vulgaris)*
7.2.1. Introduction
7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3. Flat wart, or plane wart (verruca plana)
7.4. Plantar wart, or verruca (verruca plantaris)
7.5. Genital wart (condyloma acuminatum)
7.6. Others( Periungual wart, Filiform wart, Mosaic warts)
8. BY TREATMENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Physical Destruction*
8.2.1.1. Introduction
8.2.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.2.2. Cryotherapy (Freezing)
8.2.3. Surgical Removal
8.2.4. Laser Treatment
8.2.5. Others
8.3. Medication
8.3.1. Chemical Destruction
8.3.1.1. Bleomycin intralesional
8.3.1.2. Cantharidin (VP-102)
8.3.1.3. Salicylic Acid
8.3.1.4. Others
8.3.2. Immunomodulatory agent
8.3.2.1. Imiquimod 5% - topical
8.3.2.2. Interferon - intralesional
8.3.2.3. Dinitrochlorobenzene - topical
8.3.2.4. Diphencyprone topical
8.3.2.5. Retinoids - topical or oral
8.3.2.6. Others
8.3.3. Vaccines
8.3.3.1. Human papillomavirus vaccine, nonavalent (Gardasil 9)
8.3.3.2. Cervarix
8.3.4. Keratolytics
8.3.4.1. Podophyllum resin (Podocon-25, Podo-Ben-25, Podofin)
8.3.4.2. Podofilox (Condylox)
8.3.4.3. Trichloroacetic acid topical (Tri-Chlor)
8.3.4.4. 5-Fluorouracil (Efudex, Fluoroplex)
8.3.4.5. Others
8.3.5. Kunecatechins (Veregen)
8.3.6. Other
9. BY END-USER
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User Segment
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Others
10. BY REGION
10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.3. Market Attractiveness Index, By Region
10.4. North America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. U.S.
10.4.6.2. Canada
10.4.6.3. Mexico
10.5. Europe
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. Germany
10.5.6.2. U.K.
10.5.6.3. France
10.5.6.4. Italy
10.5.6.5. Spain
10.5.6.6. Rest of Europe
10.6. South America
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.6.7.1. Brazil
10.6.7.2. Argentina
10.6.7.3. Rest of South America
10.7. Asia Pacific
10.7.1. Introduction
10.7.2. Key Region-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.7.6.1. China
10.7.6.2. India
10.7.6.3. Japan
10.7.6.4. Australia
10.7.6.5. Rest of Asia Pacific
10.8. Middle East and Africa
10.8.1. Introduction
10.8.2. Key Region-Specific Dynamics
10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. COMPANY PROFILES
12.1. Merck & Co., Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Dr. Scholl’s
12.3. Mylan N.V.
12.4. Novan Inc.
12.5. Pfizer, Inc.
12.6. GlaxoSmithKline plc,
12.7. Teva Pharmaceutical Industries Ltd
12.8. Verrica Pharmaceuticals
12.9. Phio Pharmaceuticals Corp.
12.10. AIM ImmunoTech, Inc. (List Not Exhaustive)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us
